[ANIK] Anika Therapeutics Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 49.53 Change: 0.9 (1.85%)
Ext. hours: Change: 0 (0%)

chart ANIK

Refresh chart

Description: Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company?s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company?s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regen

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS2.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -40.93% Sales Growth - Q/Q-33.26% P/E21.89
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA13.56% ROE14.74% ROI
Current Ratio23.7 Quick Ratio21.67 Long Term Debt/Equity Debt Ratio0.03
Gross Margin76.03% Operating Margin49.46% Net Profit Margin30.77% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.9 M Cash From Investing Activities-6.01 M Cash From Operating Activities3.98 M Gross Profit17.63 M
Net Profit7.82 M Operating Profit12.43 M Total Assets208.01 M Total Current Assets155.73 M
Total Current Liabilities7.96 M Total Debt Total Liabilities17.44 M Total Revenue22.9 M
Technical Data
High 52 week68.43 Low 52 week43.78 Last close43.98 Last change-0.97%
RSI32.42 Average true range1.17 Beta0.54 Volume53.19 K
Simple moving average 20 days-4.63% Simple moving average 50 days-13.01% Simple moving average 200 days-18.62%
Performance Data
Performance Week-3.4% Performance Month-10.65% Performance Quart-29.55% Performance Half-26.2%
Performance Year-1.96% Performance Year-to-date-18.42% Volatility daily1.44% Volatility weekly3.21%
Volatility monthly6.58% Volatility yearly22.81% Relative Volume229.99% Average Volume106.58 K
New High New Low


2019-03-18 08:30:00 | Anika Appoints Robert Richard, Ph.D. as Vice President of Research and Development

2019-03-11 16:05:00 | Anika to Showcase Commercial and Pipeline Portfolio at 2019 AAOS Annual Meeting

2019-03-06 02:20:36 | Edited Transcript of ANIK earnings conference call or presentation 27-Feb-04 4:00pm GMT

2019-03-06 02:18:14 | Edited Transcript of ANIK earnings conference call or presentation 17-Mar-10 1:00pm GMT

2019-02-22 09:46:10 | Anika Therapeutics ANIK Q4 2018 Earnings Conference Call Transcript

2019-02-22 00:10:42 | Edited Transcript of ANIK earnings conference call or presentation 21-Feb-19 10:00pm GMT

2019-02-21 18:55:11 | Anika Therapeutics ANIK Q4 Earnings and Revenues Top Estimates

2019-02-21 18:01:32 | Anika: 4Q Earnings Snapshot

2019-02-21 16:05:00 | Anika Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-20 12:05:41 | How Financially Strong Is Anika Therapeutics, Inc. NASDAQ:ANIK?

2019-02-14 10:31:03 | Analysts Estimate Anika Therapeutics ANIK to Report a Decline in Earnings: What to Look Out for

2019-02-07 16:05:00 | Anika to Issue Fourth-Quarter and Full-Year 2018 Financial Results and Business Highlights on Thursday, February 21

2019-02-01 07:35:00 | New Research: Key Drivers of Growth for Cisco, Landstar System, Central Garden & Pet, Anika Therapeutics, Hibbett Sports, and MoneyGram International — Factors of Influence, Major Initiatives and Sustained Production

2019-01-21 11:58:50 | When Should You Buy Anika Therapeutics, Inc. NASDAQ:ANIK?

2019-01-16 16:05:00 | Anika Announces Plans to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society ICRS Summit in San Diego

2019-01-14 09:30:02 | ANIK or TECH: Which Is the Better Value Stock Right Now?

2018-12-27 15:13:09 | 6 Undervalued Stocks With Positive Earnings Growth Estimates

2018-12-24 09:26:02 | Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder

2018-12-23 12:00:52 | Hedge Funds Are Dumping Anika Therapeutics, Inc. ANIK

2018-12-21 09:19:02 | Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead

2018-12-20 12:39:53 | Do You Know What Anika Therapeutics, Inc.’s NASDAQ:ANIK P/E Ratio Means?

2018-12-17 09:30:02 | ANIK vs. RGEN: Which Stock Should Value Investors Buy Now?

2018-12-14 07:59:12 | 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

2018-12-14 07:57:12 | Anika Therapeutics Enters Oversold Territory

2018-12-12 08:00:00 | Anika to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society ICRS Focus Meeting in Milan

2018-12-10 08:44:01 | Why Abeona Therapeutics ABEO Could Be Positioned for a Slump

2018-12-04 16:05:00 | Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX

2018-11-13 14:43:07 | Is Anika Therapeutics Inc’s NASDAQ:ANIK ROE Of 7.5% Concerning?

2018-11-02 08:55:00 | New Research: Key Drivers of Growth for Edison International, NuVasive, LogMein, Anika Therapeutics, First Industrial Realty Trust, and ON Semiconductor — Factors of Influence, Major Initiatives and Sustained Production

2018-10-29 09:30:01 | ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?

2018-10-25 10:16:01 | Edited Transcript of ANIK earnings conference call or presentation 24-Oct-18 9:00pm GMT

2018-10-25 08:03:26 | The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

2018-10-24 20:02:55 | Anika Therapeutics Inc ANIK Q3 2018 Earnings Conference Call Transcript

2018-10-24 17:25:09 | Anika Therapeutics ANIK Q3 Earnings Beat Estimates

2018-10-24 16:17:50 | Anika: 3Q Earnings Snapshot

2018-10-24 16:05:00 | Anika Reports Third Quarter 2018 Financial Results

2018-10-24 08:30:00 | Susan Vogt Appointed to Board of Directors of Anika Therapeutics

2018-10-22 11:22:03 | What's in Store for Anika Therapeutics ANIK in Q3 Earnings?

2018-10-17 10:32:02 | Anika Therapeutics ANIK Q3 Earnings Preview: What to Look Out For

2018-10-11 08:15:00 | Market Trends Toward New Normal in Park Hotels & Resorts, Safety Insurance Group, Cincinnati Financial, Anika Therapeutics, CME Group, and Midstates Petroleum — Emerging Consolidated Expectations, Analyst Ratings

2018-10-10 16:05:00 | Anika to Issue Third-Quarter 2018 Financial Results and Business Highlights on Wednesday, October 24

2018-09-28 10:58:02 | Ultragenyx Reports Top-line Data From Gene Therapy Candidate

2018-09-27 08:49:12 | AVEO Pharmaceuticals AVEO Soars: Stock Adds 6.4% in Session

2018-09-26 08:59:12 | Novavax NVAX Catches Eye: Stock Jumps 7.6%

2018-09-25 11:18:03 | Arena ARNA Posts Favorable Top-Line Data on Pain Candidate

2018-09-25 10:52:02 | FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study

2018-09-25 10:44:02 | FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program

2018-09-25 08:50:12 | Alexion Pharmaceuticals ALXN Surges: Stock Moves 5.3% Higher

2018-09-05 16:05:00 | Anika Appoints Dr. Cheryl Blanchard to Its Board of Directors

2018-09-05 16:05:00 | Anika to Participate in the 2018 Morgan Stanley Global Healthcare Conference on September 12, 2018